Trials / Completed
CompletedNCT00960557
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Mateon Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combretastatin A1 Diphosphate (OXi4503) | OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle. |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2009-08-18
- Last updated
- 2011-08-23
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00960557. Inclusion in this directory is not an endorsement.